Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Sintilimab and IBI305 Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma

Next Previous
Trial Profile

A Randomized, Open-label Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Sintilimab and IBI305 Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 23 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Sintilimab (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ORIENT-32
  • Sponsors Innovent Biologics

Most Recent Events

  • 21 Jan 2023 Results assessing adverse events of special interest (AESIs), presented at the 2023 Gastrointestinal Cancers Symposium.
  • 21 Jan 2023 Updated results of objective response rate (ORR), time to response (TTR), duration of response (DoR) and depth of response (DpR) were presented at the 2023 Gastrointestinal Cancers Symposium.
  • 16 Mar 2022 Efficacy data from this study used to evaluate the cost-effectiveness of sintilimab plus bevacizumab versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma (HCC) in China to provide economic evidence to inform health decision making published in the Advances in Therapy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top